Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03729869 · ClinicalTrials.gov registry record · Phase 2

Impact of Progesterone on Stress Reactivity and Cannabis Use

A Phase 2 study of Cannabis Use, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
148
Enrollment target
1
Study location

NCT03729869 is a Phase 2 study of Cannabis Use that has completed, run by Medical University of South Carolina. The registered enrollment target is 148 participants, below the 276-participant average among 44 other Cannabis Use trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03729869, a Phase 2 study of Cannabis Use, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
148 participants
Enrollment target
1
Study location

Study Summary

This is a research study to find out if a hormone called progesterone affects marijuana users' stress response and marijuana use. Progesterone is a naturally occurring sex hormone involved in the menstrual cycle and reproduction, and has been shown to reduce withdrawal symptoms when people stop using substances like cocaine and nicotine. It is not FDA approved for treating cannabis users and is considered an investigational drug in this study.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Progesterone

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2019-01-18
Est. Completion 2022-11-09
Phase Phase 2

What the Registry Record Tells You About NCT03729869

The ClinicalTrials.gov registry entry for NCT03729869 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 276-participant average among 44 other Cannabis Use trials with a reported enrollment target (46% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cannabis Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03729869 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT03729869 about?

NCT03729869 is a clinical study titled "Impact of Progesterone on Stress Reactivity and Cannabis Use". This is a research study to find out if a hormone called progesterone affects marijuana users' stress response and marijuana use. Progesterone is a naturally occurring sex hormone involved in the menstrual cycle and reproduction, and has been shown to reduce withdrawal symptoms when people stop usin...

What is the current status of trial NCT03729869?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2019-01-18. Estimated completion is 2022-11-09.

What conditions does trial NCT03729869 study?

This clinical trial studies the following conditions: Cannabis Use.

What interventions are being tested in trial NCT03729869?

The interventions under investigation include: Placebo (DRUG), Progesterone (DRUG).

Who is sponsoring clinical trial NCT03729869?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03729869 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cannabis Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.